Compounded Peptides and the New HHS Policy: What Changed and What Didn't
On October 28, 2026, the U.S. Department of Health and Human Services (HHS) said it won't take action against licensed 503A pharmacies that make six compounded peptides: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax. That isn't FDA approval. It's a draft policy with strict conditions, and it lasts only until the FDA writes a final rule.
If your feed has been telling you peptides are "legal now," the real story is more specific than that. This guide breaks down what changed, what didn't, and what to watch next.
What "enforcement discretion" means (and what it doesn't)
Enforcement discretion means the government is choosing not to act against something, for now. In this case, HHS is saying it won't go after licensed compounding pharmacies that make these six peptides, as long as they follow the policy's conditions.
It doesn't mean the peptides are approved. So, is BPC-157 FDA approved? No. None of the six peptides on this list are FDA-approved, and the policy doesn't say whether they're safe or effective. It only addresses whether pharmacies can compound them while the FDA finishes its review.
Is BPC-157 legal, then? Licensed 503A pharmacies that meet every condition can now compound it without facing federal enforcement, while the rules are finalized. Products sold as "research peptides" are a different story, which we cover below.
There's also an interesting backstory. When the FDA's Pharmacy Compounding Advisory Committee met in July 2026, the FDA's own scientists recommended against adding any of the six peptides to the list of substances pharmacies can compound. The committee voted to recommend them anyway. For BPC-157, TB-500 and KPV, the vote was 8 to 6. Close.
What happens next: The policy is still a draft. Public comments close November 13, 2026. After that, the FDA will write a final rule for each peptide, and HHS can revise or withdraw the policy at any time. State pharmacy boards can also set their own limits, so what's allowed may vary by state.
The six peptides covered
A quick, plain-English look at each one. The research on all six is still early, and we'll go deeper on each in future posts.
- BPC-157: A 15-amino-acid peptide based on a protein found in human stomach juice. Researchers in Croatia first described it in 1993.
- TB-500: A lab-made copy of seven amino acids from thymosin beta-4, a protein your body makes that's involved in how cells move.
- KPV: Just three amino acids long. It's a small piece of alpha-MSH, a hormone your body makes that's involved in inflammation signaling.
- MOTS-c: A 16-amino-acid peptide coded in your mitochondria's own DNA, first identified in 2015. Your body makes more of it when you exercise.
- Epitalon: A four-amino-acid, lab-made peptide based on an extract from the pineal gland, the gland that makes melatonin. It was developed by researchers in Russia.
- Semax: A seven-amino-acid peptide built from a small piece of ACTH, a hormone your brain makes. It's used in stroke care in Russia but has never been approved in the U.S.
The fine print: what compounded peptides must meet
The policy comes with a list of conditions. These are the three that matter most if you're considering compounded peptides.
1. Licensed 503A pharmacies only
A 503A pharmacy is a state-licensed compounding pharmacy that prepares medication for an individual patient based on a prescription. The policy doesn't cover larger outsourcing facilities, and it doesn't cover anyone selling peptides outside a pharmacy.
2. One peptide per product
Each product can contain only one of the six peptides. That rules out blends, like BPC-157 and TB-500 combined in a single vial, which are common online.
3. Tested ingredients and safety reporting
Raw materials must come from FDA-registered manufacturers, with a certificate of analysis showing they were tested for identity, purity, strength and contaminants. Pharmacies also have to report serious side effects and quality problems to the FDA and to the states they ship to, and every label has to say it's a compounded drug that isn't for resale.
Why "research peptides" still aren't covered
Peptides sold online or in stores as "research use only" get no protection under this policy. They aren't made by licensed pharmacies, they aren't prescribed, and they don't have to meet any of the conditions above.
That gap matters. When a University of Iowa chemistry researcher tested a vial labeled retatrutide that had been bought at a Brooklyn corner store, he found no peptide at all. It was mostly a filler chemical, plus at least 13 kinds of bacteria.
That's the mess this policy is trying to clean up: moving peptides into licensed pharmacies, with testing and oversight, so people aren't left guessing what's in a vial.
Getting compounded peptides the right way
Interest in compounded peptides is growing fast, and the science behind them is still unfolding. That's what makes this such an exciting moment, and why where your peptides come from matters so much.
EverPrime will offer all six peptides soon. Each one will be compounded in the U.S. by a licensed 503A pharmacy, third-party tested, and prescribed only by a licensed clinician after a full intake.
Have questions about compounded peptides, or want to know when they're available? Contact our team.
This article is for educational purposes only and isn't medical advice. Compounded medications are not FDA-approved, and the FDA has not reviewed them for safety, effectiveness or quality. Talk to a licensed clinician before starting any new treatment.
Sources
.webp)
